A Newborn with Congenital Hyperinsulinism having a Novel Homozygous Mutation in the ABCC8 Gene

Pritesh Patel¹, Pooja Patel², Sachin Shah³

¹,²Fellow in Neonatology, ³HOD of Neonatology in Anand Children Hospital, Surat, Gujarat

Abstract: Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in newborns and infants. It is characterized by the unregulated secretion of insulin from pancreatic B-cells in relation to blood glucose concentration[1]. It occurs in sporadic and familial forms. The incidence of sporadic form is 1:40,000 live birth and familial form is 1:2,500 live birth [2]. The clinical manifestations range from life threatening hypoglycemia, presenting on first day of life to only mild symptomatic hypoglycemia. Infant usually present in the first month of life with hypothermia, hypotonia, seizures and loss of consciousness. The delay in the diagnosis and management is the major cause of permanent brain damage and neurological deficits [3, 4]. Nine gene have been reported to be associated with CHI and most common with autosomal recessive mutation in either ABCC8 or KCNJ11, located on chromosome 11p, encode, sulfonylurea receptor 1 (SUR 1) and Kir6.2 respectively, which are substitute of adenosine triphosphate, sensitive potassium channel (K -ATP) [5]. Mutations are found in only 50% of cases while in remaining 50%, the genetic etiology remains unknown [6]. We present the case of a newborn with severe CHI due to novel homozygous recessive mutation in the ABCC8 gene.

1. Introduction

Congenital hyperinsulinism (CHI) is genetic disorder characterized by inappropriately excessive secretion of insulin from pancreatic B-cells in relation to blood glucose concentration[1]. It occurs in sporadic and familial forms. The incidence of sporadic form is 1:40,000 live birth and familial form is 1:2,500 live birth [2]. The clinical manifestations range from life threatening hypoglycemia, presenting on first day of life to only mild symptomatic hypoglycemia. Infant usually present in the first month of life with hypothermia, hypotonia, seizures and loss of consciousness. The delay in the diagnosis and management is the major cause of permanent brain damage and neurological deficits [3, 4]. Nine gene have been reported to be associated with CHI and most common with autosomal recessive mutation in either ABCC8 or KCNJ11, located on chromosome 11p, encode, sulfonylurea receptor 1 (SUR 1) and Kir6.2 respectively, which are substitute of adenosine triphosphate, sensitive potassium channel (K -ATP) [5]. Mutations are found in only 50% of cases while in remaining 50%, the genetic etiology remains unknown [6]. We present the case of a newborn with severe CHI due to novel homozygous recessive mutation in the ABCC8 gene.

2. Case Summary

A 38 week gestational age baby girl (birth weight -3.0 kilogram) was born to 28 year-old G1P3 A1L2 non-consanguinuty married, non-diabetic mother by normal vaginal delivery with normal birth events with apgar score 9/10 at 1 and 5minutes respectively. Baby had no dysmorphic features or congenital anomaly. Maternal history of any chronic disease or medication was negative. Breast feeding was started just after the first evaluation. On 2nd day of life, presented with lethargy, staring look, decreased activity and simultaneous RBS was 31mg/dl. She was treated with dextrose 10% bolus (2 ml/kg) followed by Glucose infusion at 6mg/kg/min. Infusion rate was increased up to 12mg/kg/min to keep blood the blood glucose level >45mg/dl. Antibiotics therapy was started with suspected sepsis and discontinued when blood culture was negative. Laboratory investigations at time of hypoglycemia.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>measured</th>
<th>parameter</th>
<th>measured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose</td>
<td>16 mg/dl</td>
<td>Serum Acetone</td>
<td>Absent</td>
</tr>
<tr>
<td>Serum insulin</td>
<td>29 ulU/ml</td>
<td>Urine Acetone</td>
<td>Absent</td>
</tr>
<tr>
<td>Serum cortisol</td>
<td>244 ug/dl</td>
<td>U.Reducing Substance</td>
<td>Absent</td>
</tr>
<tr>
<td>Serum Ammonia</td>
<td>48 umol/L</td>
<td>Urine ketone</td>
<td>Absent</td>
</tr>
<tr>
<td>S. growth hormone</td>
<td>19.4mg/ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Baby was screened for CHI. Metabolic screen tests including ABGA, serum ammonia, thyroid function test, tandem mass spectrometry were normal. Ultrasonography of brain and abdomen, MRI brain and CT abdomen and pelvic, echocardiography were normal. As per advice by pediatric endocrinologist baby was started diazoxide (10 mg/kg/day) and octreotide (10 ug/kg/day) in addition to high Glucose infusion (12mg/kg/min). Blood glucose levels were transiently increased to 340-480mg/dl range. On 12th day of life octreotide was increased up to 30 ug/kg/day, diazoxide (20mg/kg/day) in addition to high glucose infusion(15mg/kg/min) and started hydrochlothiazide (2mg/kg/day) because of glucose levels were below 60mg/dl. On 24th day of life Nifedipine (1mg/kg/day) was added to the treatment with high calorie formula. On 35th day of life, long acting octreotide (1ug/kg/dose) 2 doses with 1 month interval was given, which decreased in glucose requirement and wean to 2 hourly feeding with intermittent glucose infusion at 8-10mg/kg/min. After 6 week, maximum tolerate dose of diazoxide(20mg/kg/day), octreotide(20ug/kg/day) and hydrochlorothiazide (2mg/kg/day) needed to keep random blood glucose levels > 70mg/dl with intermittent episode of hypoglycemia. Loading dose followed by maintenance dose of Phenobarbital was continued. On 2 month of life baby was referred to endocrinologist where repeat MRI brain and CT abdomen were done showed no significant diagnostic pathology was detected. Somatostatin receptor PET- CT and addendum to ⁶⁸Ga dotatate PET - CT showed mild diffuse somatostatin receptor expression seen in entire pancreas (?nesidioblastosis) and focal expression in liver segment IVb,

<table>
<thead>
<tr>
<th>Parameter</th>
<th>measured</th>
<th>parameter</th>
<th>measured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose</td>
<td>16 mg/dl</td>
<td>Serum Acetone</td>
<td>Absent</td>
</tr>
<tr>
<td>Serum insulin</td>
<td>29 ulU/ml</td>
<td>Urine Acetone</td>
<td>Absent</td>
</tr>
<tr>
<td>Serum cortisol</td>
<td>244 ug/dl</td>
<td>U.Reducing Substance</td>
<td>Absent</td>
</tr>
<tr>
<td>Serum Ammonia</td>
<td>48 umol/L</td>
<td>Urine ketone</td>
<td>Absent</td>
</tr>
<tr>
<td>S. growth hormone</td>
<td>19.4mg/ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
V. Sequence analysis study showed homozygous for a novel ABCC8 gene at Exon 9 in frame delete mutation c.1335_1364del, which results in the deletion of 9 amino acids(p.I446-I455del) which consistent with diagnosis of autosomal recessive CHI. Fourteen days of antibiotics course was completed for Enterobacter aerogenes sepsis. Baby was referred back to parent hospital. After 3 month, IV fluids were discontinued gradually and lengthen the daytime feedings to 3 hourly. However the patient had intermittent hypoglycemic episodes and medical treatment with diazoxide (20mg/kg/day), octreotide (20 ug/kg/day) and hydrochlorothiazide(2mg/kg/day) with blood glucose levels were maintain above >60mg/dl. Patient was discharged home on treatment at 3.5 month of age. She planned to be followed up by pediatric endocrinologist and pediatric department. At 6 month of age follow up MRI brain and EEG was done as patient had intermittent episode of seizure revealed no abnormality so phenobarbiton was stopped. Currently she is 7 month, having weight of 7.4 kg and height of 69cm and on octreotide (15ug/kg/day), diazoxide (10mg/kg/day) and hydrochorthiazide (2mg/kg/day). Neurological assessment showed minimal delay in development.

3. Discussion

In this report, we present a case of newborn with CHI. Congenital hyperinsulinism is the most common cause of persistent hypoglycemia in early infancy. Hyperinsulinemic hypoglycaemia (HH) in newborn period can be transient or persistent. Mosty transient forms of HH are secondary to maternal diabetes, intrauterine growth retardation, birth asphyxia or Rhesus isoimmunization. Persistent HH might be congenital or associated with metabolic disorders such as congenital glycosylation defects and tyrosinemia type 1 and the rare causes such as insulinoma, insulin-receptor gene defects [7]. The absence of ketosis during hypoglycemia rule out fasting or inadequate calorie intake Hypopituitarism, adrenal insufficiency, inborn error of enzyme deficiencies, galactosemia and fructosemia[8]. Serum Ammonia is high in hyperinsulinsimhyperammoniasis syndrome (HI/HA)[9]. Normal physical examination excluded Beckwith Wiedemens syndrome [10]. Tandem -MS, Urinary organic acid and reducing substance rule out short chain L-3 hydroxyacyl-coa dehydrogenase (SCHAD) [11]. Diagnostic criteria for CHI are an increased glucose requirement>8 mg/kg/min, detectable serum insulin when blood glucose <45 mg/dl, absence of ketonuria and glycemic response to glucagon[12]. CHI can be caused by mutation in nine different genes, namely ABCC8, KCNJ11, GLUD1, CGK, HADH,LC16A1, HNF 4A and UCP2 gene[5,13]. The most cases of CHI are caused by autosomal recessive mutations in the ABCC8 and KCNJ11 genes that are located on chromosome 11p15.1 encoding the two subunits of the pancreatic B-cell K-ATP channel. The pancreatic K-ATP channel is a functional complex of sulfonylurea receptor 1 (SUR1), encoded by the ABCC8 gene and an inward rectifier potassium channel subunit (Kir6.2), encoded by the KCNJ11 gene. Inactivating mutations in these genes loss of KATP channel activity resulting in membrane depolarization of the B-cells which opens the voltage-gated calcium channels and raises intracellular calcium concentrations and persistent and unregulated hypersecretion of insulin. Thesemutations tend to cause diffuse disease with intractable hypoglycemia, poor response to diazoxide. Autosomal dominant form of CHI is mostly caused by activating mutations in the glucokinase (GCK) gene or regulatory mutations in the glutamate dehydrogenase(GLUD1) gene. Focal pancreatic lesions can be caused by loss of genetic material in the maternal chromosome 11p15 region and paternallyinhheritedmutation in the ABCC8/KCNJ11 genes [14]. Histologically CHI is either diffuse or focal. The diffuse type of CHI is characterized by large β-cells with abnormally large nuclei distributed throughout the whole pancreas, whereas the focal type consists of an adenomatous hyperplasia confined to one region of the pancreas. Preoperative differentiation between focal and diffuse type of CHI is very helpful in the management and should be carried out using positron emission tomography (PET) whenever possible [1]. The most important recent advance in the management of children with CHI over the past 2 decades has been the introduction of 18F-DOPA PET scanning to differentiate focal CHI from diffuse CHI [15]. Early diagnosis and adequate management are very important in order to prevent any subsequent neurologial sequelae. Prenatal diagnosis is also possible when the mutation in the index case is known. William H. Peranteau and colleagues reported, for the first time, a prenatal diagnosis of diffuse CHI in a baby with a known family mutation and sibling affected with CHI [3]. To conclude, the diagnosis and management of hyperinsulinaemichypoglycaemia in newborns remains a challenge for neonatologists and endocrinologists.

Genetic Analysis of the ABCC8 and KCNJ11 Genes

Blood samples for genetic testing from the baby and both the parents were taken in Jaslok Hospital and research centre, Mumbai. Genomic DNA was extracted from peripheral blood leukocytes by using standard procedures. The genetic sequencing was done at the university of Exeter, Exeter UK.

References


